Newswise — Houston and Monterrey, Mexico, June 15, 2026 - IntelliGenome, Inc. today announced a strategic partnership with CTR Scientific (Control Técnico y Representaciones S.A. de C.V.) to support the evaluation, commercialization, and future adoption of the CRISPR-TB Blood Test in Mexico. The partnership reflects IntelliGenome's commitment to supporting Mexico's efforts to strengthen tuberculosis (TB) detection through innovative molecular diagnostic technologies. "Mexico is a strategically important market for advancing innovative TB diagnostics," said Kurt Wehrle, Vice President of Partnerships & Strategic Alliances at IntelliGenome. "Together with CTR Scientific, we look forward to generating clinical evidence, expanding access to CRISPR-TB, and supporting Mexico's efforts to improve tuberculosis detection." "At CTR Scientific, we are committed to bringing high-value diagnostic innovation to the Mexican healthcare system," said Alan R. Criollo Ródiz, Clinical Diagnostics Manager, CTR Scientific.